Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.
|Numero di pagine||4|
|Rivista||Clinical Case Reports|
|Stato di pubblicazione||Published - 2020|
All Science Journal Classification (ASJC) codes